

Shionogi & Co., Ltd.

**Shionogi Receives Marketing and Manufacturing Approval
for Pirespa[®] 200mg Tablet
Idiopathic Pulmonary Fibrosis Treatment**

Osaka, October 16, 2008 -- Shionogi & Co., Ltd. (Head Office: Osaka; President: Isao Teshirogi) today announced that it received marketing and manufacturing approval for Pirespa[®] 200mg Tablet (generic name: Pirfenidone), an Idiopathic Pulmonary Fibrosis treatment, on October 16. It is scheduled to launch pending its National Health Insurance (NHI) price listing.

Pirespa[®] was licensed from U.S.-based Marnac, Inc. and KDL, Inc., Tokyo, and Shionogi has developed it in Japan. The Phase III clinical trials showed it significantly preserved vital capacity as a primary endpoint for Idiopathic Pulmonary Fibrosis compared to placebo, and it received marketing and manufacturing approval for the first time in the world.

Shionogi will prioritize securing the safety of patients who receive Pirespa[®] for launch ahead, and will make every effort to collect and provide information on the proper use, while following launch, we plan to conduct all-case surveillance on the patients who receive the drug.

Shionogi will do its utmost to make a larger contribution to the treatment for Idiopathic Pulmonary Fibrosis by getting Pirespa[®] properly prescribed.

For Reference:

About Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a medical condition of unknown etiology with poor prognosis in which progressive fibrosis of the alveolar walls produces irreversible “honeycomb lung”*. In general, restrictive impairment (reduction of vital capacity (VC) and total lung capacity (TLC)) is evident. As the symptom (fibrosis of the alveolar walls) progresses, gas exchange in the lungs (exchange of oxygen and carbon dioxide) becomes difficult. In some cases, oxygen therapy becomes necessary. Because of its severity, IPF is designated as a “specified disease” (in other words, an intractable disorder).

*Honeycomb lung: A high-resolution CT scan of the lung yields a honeycomb pattern.

Product Overview

Product Name: Pirespa[®] 200mg Tablet
Generic Name: Pirfenidone
Effect: Idiopathic Pulmonary Fibrosis
Form and Content: Film-coated tablet containing 200mg of Pirfenidone in one tablet
Dosage and Administration: Generally in adults, one 200mg tablet as a primary dosage is administered orally three times daily (600mg in a day) after meal. The dosage is increased by 200mg increments per admin up to 600mg per admin (1800mg in a day), examining condition of the patient. The dosage should be adjusted according to the patient’s condition.

For further information:

Shionogi & Co., Ltd. Corporate Communications Department

Osaka Tel: +81-6-6209-7885 Fax: +81-6-6229-9596

Tokyo Tel: +81-3-3406-8164 Fax: +81-3-3406-8099